Search results
Results from the WOW.Com Content Network
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones , such as testosterone , to grow.
Testosterone suppression; Androgen ablation; Androgen deprivation [ edit on Wikidata ] Androgen suppression , also known as testosterone suppression , is a medical treatment to suppress or block the production or action of male sex hormones , typically used against certain cancers that rely on male growth hormones.
Antiandrogens that are currently on the market are particularly useful for the treatment of prostate cancer during the early stages. However, prostate cancer often progresses to a hormone-refractory state in which the cancer progresses in the presence of continued androgen ablation or antiandrogen therapy. [9]
The most common methods of androgen deprivation therapy currently employed to treat prostate cancer are castration (with a GnRH modulator or orchiectomy), nonsteroidal antiandrogens, and the androgen synthesis inhibitor abiraterone acetate. [16] Castration may be used alone or in combination with one of the other two treatments.
SRT is often administered in combination with androgen deprivation therapy for up to two years. A retrospective study of patients treated with SRT between 1987 and 2013 found that 56% of 2460 patients were free from biochemical failure after 5 years follow-up. [82] Among those with a PSA less than 0.2 before SRT, this was 71%.
Triple androgen blockade (TrAB) is a method of ADT in which a 5α-reductase inhibitor such as finasteride or dutasteride is added to CAB. [ 2 ] [ 3 ] MAB has been found to produce higher rates of gynecomastia (7 to 28%) than orchiectomy and GnRH analogues alone (1 to 16%), but lower rates than nonsteroidal antiandrogen monotherapy such as with ...
SPCG-15 – radical prostatectomy versus radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer [3] [34] The SPCG-6 study was also known as Trial 25 of the Early Prostate Cancer (EPC) clinical trial programme. [35] [18] [19] [20] [21]
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...